MarginsXMarginsX
Home › Markets › Health Care › CMMB

Chemomab Therapeutics Ltd. American Depositary Share (CMMB)

CMMB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.62
+5.88% on the day
Market cap
$13.0M
Nano cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCMMB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO year2019
SEC CIK0001534248

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
8.2 months
$7.6M cash at December 31, 2025
Share count, 1 year
+52.6%
2024-12-31 to 2025-12-31 · +160.4% over 3 years
Going-concern doubt
Yes
20-F filed March 23, 2026
Insider net buying, 12 months
$14K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about our ability to continue as a going concern."
20-F 2026-03-23
Cash and burn$7.6M cash; operating cash flow -$2.8M a quarter.Report 2025-12-31
Shares outstanding7,192,267 (2025-12-31); 4,714,153 a year earlier; 2,762,453 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorSomekh Chaikin, Tel Aviv, IsraelPCAOB Form AP 2026-04-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $20K, sold $7K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$9.0M-$11.1M$7.6MNo debt tagsNeeds four quarters20-F 2026-03-23
Q1 2023
2023-03-31
Not filed-$8.8M-$7.2M$20.8MNo debt tagsNeeds four quarters10-Q 2023-05-11
Q4 2022
2022-12-31
Not filed-$8.3M-$5.7M$13.5MNo debt tagsNeeds four quarters20-F 2025-04-04
Q3 2022
2022-09-30
Not filed-$8.1M-$5.3M$10.7MNo debt tagsNeeds four quarters10-Q 2022-11-10
Q2 2022
2022-06-30
Not filed-$6.2M-$5.7M$9.9MNo debt tagsNeeds four quarters10-Q 2022-11-10
Q1 2022
2022-03-31
Not filed-$5.1M-$3.7M$13.8MNo debt tagsNeeds four quarters10-Q 2023-05-11
Q4 2021
2021-12-31
Not filed-$5.0M-$2.9M$15.2MNo debt tagsNeeds four quarters20-F 2024-03-28
Q3 2021
2021-09-30
Not filed-$3.0M-$2.6M$37.7MNo debt tagsNeeds four quarters10-Q 2022-11-10

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week+15.9%
1 month+23.4%
3 months-19.5%
Year to date-7.3%
1 year-40.0%
From 52-week high-45.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
KYNBKyntra Bio Inc.$3.20-8.31%$13.0M
NEUPNeuphoria Therapeutics Inc.$2.48-2.75%$13.4M
OPTHOptimi Health Corp. Common Shares$2.15-4.44%$12.3M
MRKRMarker Therapeutics Inc.$0.8286-4.76%$13.8M
ALLRAllarity Therapeutics Inc.$0.8752-8.24%$13.9M
QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares$1.44-10.56%$12.2M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M
LSTALisata Therapeutics Inc.$1.09-9.92%$11.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier